Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK+) lung cancers; yet the durability of response is limited by drug resistance. Elucidation of on-target resistance mechanisms...
Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK~+) lung cancers; yet the durability of response is limited by drug resistance. Elucidation of on-target resistance ...
All ALK-positive and ALK-negative controls had advanced NSCLC. ALK-positive patients treated with crizotinib had a one-year overall survival rate of 74% and a two-year overall survival rate of 54%. Median overall survival had not been reached. This compared with outcomes for the ALK...
ALK-positive advanced non-small cell lung cancer 青云英语翻译 请在下面的文本框内输入文字,然后点击开始翻译按钮进行翻译,如果您看不到结果,请重新翻译! 翻译结果1翻译结果2翻译结果3翻译结果4翻译结果5 翻译结果1复制译文编辑译文朗读译文返回顶部 正在翻译,请等待......
First-line crizotinib versus chemotherapy in ALK-positive lung cancer N Engl J Med, 371 (2014), pp. 2167-2177 doi:10.1056/NEJMoa1408440 CrossrefView in ScopusGoogle Scholar 8. B.J. Solomon, D.-W. Kim, Y.-L. Wu, et al. Final overall survival analysis from a study comparing first-li...
"ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature." Mod Pathol 20(3): 310-319.Reichard KK, McKenna RW, Kroft SH. ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. Mod Pathol 2007;20:310-19....
The-Lancet_2017_Alectinib-versus-crizotinib-in-patients-with-ALK-positive-non-small-cell-lung-cancer-J-ALEX-an-open-label-randomised-phase-3-trial 热度: pembrolizumab as first-line therapy for patients with pd-l1-positive advanced non-small cell lung cancer_ a phase 1 trial.[2017][ann oncol...
ALK-positivechemotherapynon-small-cell lung cancerLung cancer, a significant global health challenge, notably the non-small-cell lung cancer (NSCLC) subtype, is a topic of utmost importance. The continuous advancements in NSCLC treatment, especially in the context of anaplastic lymphoma kinase (ALK)...
In the present review we will briefly discuss the current knowledge of ALK-positive advanced non-small cell lung cancer. Also, we will touch upon new developments on drugs/combination regimens aimed at inhibiting the ALK-TK, in an attempt to delineate how treatment of ALK-positive disease may ...
ALK-positive diffuse large B-cell lymphoma: Report of four cases and review of the literature. J Hematol Oncol 2009;2:11. B Beltran,J Castillo,R Salas,... - 《Journal of Hematology & Oncology》 被引量: 0发表: 2009年 Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma presen...